Katja Wingenfeld1, Linn K Kuehl2, Isabel Dziobek3, Stefan Roepke2, Christian Otte2, Kim Hinkelmann2. 1. Department of Psychiatry and Psychotherapy, Charité University Medical Center, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany. katja.wingenfeld@charite.de. 2. Department of Psychiatry and Psychotherapy, Charité University Medical Center, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany. 3. Berlin School of Mind and Brain, Humboldt-University Berlin, Berlin, Germany.
Abstract
BACKGROUND: The mineralocorticoid receptor (MR) is highly expressed in the hippocampus and prefrontal cortex and is involved in social cognition. We recently found that pharmacological stimulation of the MR enhances emotional empathy but does not affect cognitive empathy. In the current study, we examined whether blockade of the MR impairs empathy in patients with major depressive disorder (MDD) and healthy individuals. METHODS: In a placebo-controlled study, we randomized 28 patients with MDD without psychotropic medication and 43 healthy individuals to eitherplacebo or 300 mg spironolactone, a MR antagonist. Subsequently, all participants underwent two tests of social cognition, the Multifaceted Empathy Test (MET) and the Movie for the Assessment of Social Cognition (MASC), measuring cognitive and emotional facets of empathy. RESULTS: In the MET, we found no significant main effect of treatment or main effect of group for cognitive empathy but a highly significant treatment by group interaction (p < 0.01). Patients had higher cognitive empathy scores compared to controls in the placebo condition but not after spironolactone. Furthermore, in the spironolactone condition reduced cognitive empathy was seen in MDD patients but not in controls. Emotional empathy was not affected by MR blockade. In the MASC, no effect of spironolactone could be revealed. CONCLUSION: Depressed patients appear to exhibit greater cognitive empathy compared to healthy individuals. Blockade of MR reduced cognitive empathy in MDD patients to the level of healthy individuals. Future studies should further clarify the impact of MR functioning on different domains of social cognition in psychiatric patients.
RCT Entities:
BACKGROUND: The mineralocorticoid receptor (MR) is highly expressed in the hippocampus and prefrontal cortex and is involved in social cognition. We recently found that pharmacological stimulation of the MR enhances emotional empathy but does not affect cognitive empathy. In the current study, we examined whether blockade of the MR impairs empathy in patients with major depressive disorder (MDD) and healthy individuals. METHODS: In a placebo-controlled study, we randomized 28 patients with MDD without psychotropic medication and 43 healthy individuals to either placebo or 300 mg spironolactone, a MR antagonist. Subsequently, all participants underwent two tests of social cognition, the Multifaceted Empathy Test (MET) and the Movie for the Assessment of Social Cognition (MASC), measuring cognitive and emotional facets of empathy. RESULTS: In the MET, we found no significant main effect of treatment or main effect of group for cognitive empathy but a highly significant treatment by group interaction (p < 0.01). Patients had higher cognitive empathy scores compared to controls in the placebo condition but not after spironolactone. Furthermore, in the spironolactone condition reduced cognitive empathy was seen in MDDpatients but not in controls. Emotional empathy was not affected by MR blockade. In the MASC, no effect of spironolactone could be revealed. CONCLUSION: Depressed patients appear to exhibit greater cognitive empathy compared to healthy individuals. Blockade of MR reduced cognitive empathy in MDDpatients to the level of healthy individuals. Future studies should further clarify the impact of MR functioning on different domains of social cognition in psychiatricpatients.
Entities:
Keywords:
Cognitive empathy; Cortisol; Emotional empathy; Major depressive disorder; Mineralocorticoid receptor; Social cognition
Authors: Xiao-Dong Wang; Gerhard Rammes; Igor Kraev; Miriam Wolf; Claudia Liebl; Sebastian H Scharf; Courtney J Rice; Wolfgang Wurst; Florian Holsboer; Jan M Deussing; Tallie Z Baram; Michael G Stewart; Marianne B Müller; Mathias V Schmidt Journal: J Neurosci Date: 2011-09-21 Impact factor: 6.167
Authors: Susanne Vogel; Floris Klumpers; Marijn C W Kroes; Krista T Oplaat; Harm J Krugers; Melly S Oitzl; Marian Joëls; Guillén Fernández Journal: Biol Psychiatry Date: 2015-02-19 Impact factor: 13.382
Authors: Christian Otte; Steffen Moritz; Alexander Yassouridis; Maike Koop; Ana Maria Madrischewski; Klaus Wiedemann; Michael Kellner Journal: Neuropsychopharmacology Date: 2006-10-11 Impact factor: 7.853
Authors: Christian Otte; Katja Wingenfeld; Linn K Kuehl; Michael Kaczmarczyk; Steffen Richter; Arnim Quante; Francesca Regen; Malek Bajbouj; Frank Zimmermann-Viehoff; Klaus Wiedemann; Kim Hinkelmann Journal: Neuropsychopharmacology Date: 2014-07-18 Impact factor: 7.853
Authors: Mehdi Farokhnia; Christopher T Rentsch; Vicky Chuong; M Adrienne McGinn; Sophie K Elvig; Eliza A Douglass; Luis A Gonzalez; Jenna E Sanfilippo; Renata C N Marchette; Brendan J Tunstall; David A Fiellin; George F Koob; Amy C Justice; Lorenzo Leggio; Leandro F Vendruscolo Journal: Mol Psychiatry Date: 2022-09-20 Impact factor: 13.437
Authors: E G Aoun; V A Jimenez; L F Vendruscolo; N A R Walter; E Barbier; A Ferrulli; C L Haass-Koffler; P Darakjian; M R Lee; G Addolorato; M Heilig; R Hitzemann; G F Koob; K A Grant; L Leggio Journal: Mol Psychiatry Date: 2017-05-02 Impact factor: 15.992